On June 5, Hengrui Medicine (01276.HK) rose 3.28% in regular trading, trading at HK$55.95/share, with trading volume of HK$95.28 million. Multiple positive catalysts converged to drive the rebound after a roughly 34% pullback from prior highs.

On the news front, Hengrui Medicine delivered its strongest-ever presence at the ASCO Annual Meeting with 91 oncology research results selected — the highest among Chinese pharmaceutical companies — including 11 oral presentations covering gastrointestinal tumors, breast cancer, lung cancer, and urological cancers. Key highlights include a global-first positive Phase III result for its HER3 ADC (SHR-A2009) in EGFR-mutant lung cancer, and significant PFS improvements for its HER2 ADC in colorectal cancer. Simultaneously, the company resumed its buyback program on June 4, repurchasing 420,000 A-shares for approximately RMB 19.82 million at prices between RMB 46.70–47.70 per share, with cumulative buybacks reaching RMB 772 million. The company reported Q1 revenue of RMB 8.14 billion (+12.98% YoY) and net profit of RMB 2.28 billion (+21.78% YoY), reinforcing its growth trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)